Market Place
Sourcing Support
All News #Library
Biotech
Mineralys Therapeutics Reports Q4 2025 Results and Business
12 Mar 2026 //
GLOBENEWSWIRE
Mineralys Therapeutics` Lorundrostat NDA Accepted By FDA
09 Mar 2026 //
GLOBENEWSWIRE
Mineralys Therapeutics Announces Q4 & FY 2025 Results, Hosts Call
09 Mar 2026 //
GLOBENEWSWIRE
Mineralys Therapeutics Discloses Inducement Awards Per Nasdaq LR
26 Feb 2026 //
GLOBENEWSWIRE
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq
11 Feb 2026 //
GLOBENEWSWIRE
Mineralys Therapeutics Launches Lorundrostat Phase 3 HTN Trial
12 Dec 2025 //
GLOBENEWSWIRE
Lorundrostat Data In Chronic Kidney Disease at ASN Kidney Week
07 Nov 2025 //
GLOBENEWSWIRE
Mineralys to Present Ph2 Lorundrostat CKD Data at ASN Kidney Week
21 Oct 2025 //
GLOBENEWSWIRE
Mineralys Completes Ph 2 EXPLORE-OSA Trial Enrollment
30 Sep 2025 //
GLOBENEWSWIRE
Mineralys Reveals Ph3 Efficacy of Lorundrostat in Hypertension
05 Sep 2025 //
GLOBENEWSWIRE
Mineralys’ Ph 3 Lorundrostat Trial Published in JAMA Journal
30 Jun 2025 //
GLOBENEWSWIRE
Mineralys Drug Lowers Blood Pressure in Yet Another Clinical Win
17 Jun 2025 //
FIERCE BIOTECH
Mineralys Therapeutics Closes Underwriters’ Option in Stock Offer
18 Mar 2025 //
GLOBENEWSWIRE
Mineralys Therapeutics: Lorundrosat Ph 2 Data Accepted for ACC Meet
17 Mar 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.